27 citations
,
August 2024 in “Frontiers in Pharmacology” This study identified both known and additional potential adverse reactions to tralokinumab in real-world use for atopic dermatitis, highlighting the importance of monitoring adverse events, especially in the first month of treatment.
24 citations
,
March 2017 in “Journal of The European Academy of Dermatology and Venereology” This study reported a significant increase in the reporting of sexual dysfunction associated with finasteride use, especially in individuals aged 31-45.
3 citations
,
May 2025 in “Frontiers in Pharmacology” This study identified known and potential novel adverse events, such as squamous cell carcinoma and dehydration, for vismodegib, underlining the importance of monitoring especially in the first two months of treatment.
2 citations
,
May 2025 in “Frontiers in Pharmacology” In this study, analysis of FDA data revealed a substantial risk of dermatologic adverse events with aromatase inhibitors, especially anastrozole and exemestane, highlighting the importance of dermatologic monitoring during such therapies.
June 2026 in “The Journal of Sexual Medicine” This study found that psychiatric adverse drug reactions were more frequently reported with finasteride than with dutasteride, but it remains unclear if there is a causal relationship.